, Volume 61, Issue 3, pp 353–364 | Cite as

An Update on the Role of Nitrofurans in the Management of Urinary Tract Infections

  • David R. GuayEmail author
Review Article


There have been few recent reviews of the nitrofurans in the literature, and none include recently available data on the use of nitrofurazone (nitrofural) in the prevention of catheter-associated urinary tract infection (CAUTI). Nitrofurazone and nitrofurantoin are the only nitrofurans that have become established in clinical use in the 20th century. These 2 nitrofurans have remained clinically useful against a wide spectrum of Gram-positive and Gram-negative bacteria, including many strains of common urinary tract pathogens. Today, the primary use of nitrofurantoin is as an oral antibacterial treatment for genitourinary infections. Nitrofurazone is primarily used as a topical antibacterial agent in burns and skin grafts and recently was approved for the prophylaxis of CAUTI. The recent development of a nitrofurazone-impregnated catheter as a novel modality in the prevention of CAUTI reflects a renewed interest in the effectiveness of nitrofurans. In an era when concern about bacterial resistance to many anti-infective agents is growing, the nitrofurans have continued to be active against organisms that have developed resistance to antibacterials. The presence of multiple mechanisms of action for the nitrofurans might be expected to reduce the ability of bacteria to develop resistance. Considering that an emergence of resistance to the nitrofurans has not appreciably occurred after several decades of clinical use, the nitrofurans may be unique among common antibacterial agents in this regard.


Urinary Tract Infection Nitrofurantoin Nitrofuran Nitrofurazone Uncomplicated Cystitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dann O, Möller ER. Bacteriostatically acting nitro compounds of thiophenes and furans. Chemische Berichte 1947; 80: 23–36CrossRefGoogle Scholar
  2. 2.
    Chamberlain RE. Chemotherapeutic properties of prominent nitrofurans. J Antimicrob Ther 1976; 2: 325–36CrossRefGoogle Scholar
  3. 3.
    AHFS drug information 1999. In: McEvoy GK, editor. Bethesda (MD): American Society of Health System Pharmacists, 1999Google Scholar
  4. 4.
    Andriole VT. Urinary tract agents: nitrofurantoin and methenamine. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. New York (NY): Churchill Livingstone, 1990: 345–9Google Scholar
  5. 5.
    Johnson JR, Berggren T, Conway AJ. Activity of a nitrofurazone matrix urinary catheter against catheter associated uropathogens. Antimicrob Agents Chemother 1993; 37(9): 2033–6PubMedCrossRefGoogle Scholar
  6. 6.
    McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother 1994; 33 Suppl. A: 23–30PubMedCrossRefGoogle Scholar
  7. 7.
    Mandell GL, Sande MA. Antimicrobial agents: sulfonamides, trimethoprim-sulfamethoxazole, quinolones, and agents for urinary tract infections. In: Goodman Gilman A, Rall TW, Nies AS, et al., editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. Elmsford: Pergamon Press, 1990: 1061Google Scholar
  8. 8.
    Asnis RE, Cohen FB, Gotts JS. Studies on bacterial resistance to furacin. Antibiot Chemother 1952; 2: 123–9Google Scholar
  9. 9.
    Breeze AS, Obaseiki-Ebor EE. Mutations to nitrofurantoin and nitrofurazone in Escherichia coli K12. J Gen Microbiol 1983; 129: 99–103PubMedGoogle Scholar
  10. 10.
    Herrlich P, Schweiger M. Nitrofurans, a group of synthetic antibiotics, with a new mode of action: discrimination of specific messenger RNA classes. Proc Natl Acad Sci U S A 1976; 73: 3386–90PubMedCrossRefGoogle Scholar
  11. 11.
    Grant DJW, DeSzoes J. Inhibitory effects of some anti-inflammatory and other analgesics and nitrofurans on the induction of beta-galactosidase synthesis in Klebsiella aerogenes. Biochem Pharmacol 1971; 20: 625–35PubMedCrossRefGoogle Scholar
  12. 12.
    McCalla DR. Nitrofurans. In: Hahn FE, editor. Mechanism of action of antibacterial agents. New York (NY): Springer-Verlag, 1979: 176–213CrossRefGoogle Scholar
  13. 13.
    Shah RR, Wade G. Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy. Adverse Drug React Acute Poisoning Rev 1989; 8: 183–201PubMedGoogle Scholar
  14. 14.
    Coffey RP, Rice TL, Thomson PD. Effect of blood and serum on in vitro antibacterial activity of nitrofurazone. Am J Hosp Pharm 1991; 48: 1496–9PubMedGoogle Scholar
  15. 15.
    Gleckman R, Alvarez S, Joubert DW. Drug therapy reviews: nitrofurantoin. Am J Hosp Pharm 1979; 36: 342–51PubMedGoogle Scholar
  16. 16.
    Macrobid® [package insert]. Cincinnati (OH): 1998Google Scholar
  17. 17.
    Proctor & Gamble. Release-NF [package insert]. Stewartville (MN): Rochester Medical Corporation, 1999Google Scholar
  18. 18.
    Marion-Landais G, Heotis JP, Mertz JL, et al. Non-absorption of nitrofurazone from the urethra in men. Curr Ther Res Clin Exp 1976 May; 19(5): 550–3PubMedGoogle Scholar
  19. 19.
    Marion-Landais G, Heotis JP, Herrett RJ, et al. Non-absorption of furazolidone from the vagina in women. Curr Ther Res Clin Exp 1975 Sep; 18(3): 510–2PubMedGoogle Scholar
  20. 20.
    Snyder ML, Kiehn CL, Christopherson JW. Effectiveness of a nitrofuran in the treatment of infected wounds. I. Preliminary report. Mil Surg 1945; 97: 380–4Google Scholar
  21. 21.
    Shipley ER, Dodd MD. Clinical observations of furacin soluble dressing in treatment of surface infections. Surg Gynecol Obstet 1947; 84: 366–72PubMedGoogle Scholar
  22. 22.
    Shipley ER. Re-evaluation of furacin as a local agent in the treatment of surface infections. Am Surg 1965; 31: 238–41PubMedGoogle Scholar
  23. 23.
    Turck M, Ronald AR, Petersdorf RG. Susceptibility of Enterobacteriaceae to nitrofurantoin correlated with eradication of bacteriuria. Antimicrob Agents Chemother 1966; 446–52Google Scholar
  24. 24.
    Atkinson B A. Species incidence and trends of susceptibility to antibiotics in the United States and other countries: MIC and MBC. In: Lorian V, editor. Antibiotics in laboratory medicine. 2nd ed. Baltimore (MD): Williams & Wilkins, 1986Google Scholar
  25. 25.
    Culp LA, Carson III CA. Antibiotic resistance in the genitourinary system. Contemp Urol 1998; 10: 58–75Google Scholar
  26. 26.
    Maartens G, Oliver SP. Antibiotic resistance in community-acquired urinary tract infections. S Afr Med J 1994; 84: 600–2PubMedGoogle Scholar
  27. 27.
    Burke JP, Riley DK. Nosocomial urinary tract infections. In: Mayhall CG, editor. Hospital epidemiology and infection control. Philadelphia (PA): Lippincott, Williams & Wilkins, 1996: 139–53Google Scholar
  28. 28.
    Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1997; 11: 609–22PubMedCrossRefGoogle Scholar
  29. 29.
    Overmeyer M. Clinicians running out of ammo as pathogens build defenses. Urol Times 1994; 22: 1–4Google Scholar
  30. 30.
    Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999; 281: 736–8PubMedCrossRefGoogle Scholar
  31. 31.
    Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999; 29: 745–58PubMedCrossRefGoogle Scholar
  32. 32.
    Brumfitt W, Hamilton-Miller JMT. Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years’ experience. J Antimicrob Chemother 1998; 42: 363–71PubMedCrossRefGoogle Scholar
  33. 33.
    Ansbach RK, Dybus KR, Bergeson RJ. Uncomplicated E. coli urinary tract infection in college women: a retrospective study of E. coli sensitivities to commonly prescribed antibiotics. Am Coll Health 1995; 43(4): 183–5CrossRefGoogle Scholar
  34. 34.
    Vosti KL. Recurrent urinary tract infection: prevention by prophylactic antibiotics after sexual intercourse. JAMA 1975; 231: 934–40PubMedCrossRefGoogle Scholar
  35. 35.
    Cohen BH, Di Saia P. Vaginal antibiotic for surgery. Bacterial evaluation of the effect of Furacin vaginal suppositories in relation to morbidity following major vaginal surgery. Conn Med 1970; 34(6): 406–10Google Scholar
  36. 36.
    Fonda DA. Clinical experience with furacin in external ocular infections. Eye Ear Nose Throat Mon 1969; 48(2): 97–102PubMedGoogle Scholar
  37. 37.
    Young RW, Pullig RM. The use of Furacin topical cream in the treatment of fire ant bites. J LA State Med Soc 1981 (1); 133: 10PubMedGoogle Scholar
  38. 38.
    Fisher AA. The role of topical medications in the management of stasis ulcers. Angiology 1971 22(4): 206–10PubMedCrossRefGoogle Scholar
  39. 39.
    Douglass CC. Nitrofurazone in the treatment of bacterial ear infections: re-evaluation after twenty years. Laryngoscope 1970; 80(3): 400–8PubMedCrossRefGoogle Scholar
  40. 40.
    Glascock Jr HW, MacLeod PF, David JB, et al. Is nitrofurazone a primary irritant or a potent sensitizer: a review of the literature, 1945–1965, and cases reported to medical director. Rev Allergy 1969; 23: 52–8PubMedGoogle Scholar
  41. 41.
    Maki DG, Holcomb RG. Areport on the randomized, controlled clinical trial of the nitrofurazone-impregnated, antibacterial, indwelling urinary catheter. Rochester (MN): Rochester Medical Corporation, 1997Google Scholar
  42. 42.
    Nickel JC, Grant SK, Costerton JW. Catheter-associated bacteriuria. An experimental study. Urology 1985; 26(4): 369–75Google Scholar
  43. 43.
    Tambyah PA, Halvorson KT, Maki DG. A prospective study of pathogenesis of catheter-associated urinary tract infections. Mayo Clin Proc 1999; 74: 131–6PubMedCrossRefGoogle Scholar
  44. 44.
    Stamm WE. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med 1991; 91(3B): 65S–71SPubMedCrossRefGoogle Scholar
  45. 45.
    Johnson JR, Delavari P, Azar M. Activities of a nitrofurazone-containing urinary catheter and a silver hydrogel catheter against multidrug-resistant bacteria characteristic of catheter-associated urinary tract infection. Antimicrob Agents Chemother 1999; 43: 2990–5PubMedGoogle Scholar
  46. 46.
    Harding GK, Nicolle LE, Ronald AR, et al. How long should catheter-acquired urinary tract infection in women be treated? A randomized, controlled study. Ann Intern Med 1991; 114: 713–9PubMedGoogle Scholar
  47. 47.
    D’Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm 1985; 19(7–8): 540–7PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, Partnering Care Senior Services, HealthPartnersUniversity of MinnesotaMinneapolis s[MinnesotaUSA

Personalised recommendations